Moderna-Merck mRNA Vaccine Cuts Melanoma Recurrence Risk by 42%

Moderna-Merck mRNA Vaccine Cuts Melanoma Recurrence Risk by 42%

Économie Santé
Connectez-vous pour épingler cet événement

Moderna and Merck said their personalized mRNA vaccine intismeran, given with Keytruda, reduced melanoma recurrence or death by 42% in a phase-3 trial. The finding was echoed in reports from Ars Technica, BioPharma Dive and NBC News, which also noted that both companies' shares fell after the announcement.

Acteurs

Moderna Merck TD Cowen RBC Capital Markets

Lieux

Wall Street, New York, United States

Vérification des faits

Comment fonctionnent ces métriques
Verdict global: Partiellement confirmé Confiance: 73% Affirmations: 5
Résumé

All five claims analyzed were partially confirmed. The claim that Merck and Moderna reported their personalized mRNA vaccine combined with Keytruda reduced the risk of death or recurrence by 42% in patients with resected melanoma on October 22, 2026, was partially confirmed. The October 23, 2026, claim about the phase III study where the Moderna-Merck vaccine intismeran reduced melanoma recurrence and death by 42% when added to Keytruda, compared to Keytruda alone, was partially confirmed. The claim dated October 25, 2026, stating that a Merck-Moderna mRNA vaccine combined with Keytruda lowered melanoma recurrence or death by 42% in a pivotal study was partially confirmed. The October 26, 2026, claim about a phase 3 study showing a 42% reduction in melanoma recurrence or death with the personalized mRNA vaccine developed by Moderna and Merck versus standard immunotherapy alone was partially confirmed. Finally, the October 22, 2026, claim that the combined vaccine and Keytruda regimen lowered distant metastasis risk by 38% in melanoma patients was also partially confirmed.

Connectez-vous ou abonnez-vous pour voir l'analyse complète avec les affirmations, les sources et la validation chronologique.

Créer un compte Se connecter

Cette section contient une vérification automatisée des affirmations à partir de sources externes et peut contenir des inexactitudes.

Articles

26 octobre 2026
1 au total
World-First Cancer Vaccine Cuts Melanoma Recurrence or Death Risk by 42% in Landmark Trial
World-First Cancer Vaccine Cuts Melanoma Recurrence or Death Risk by 42% in Landmark Trial

ScienceAlert • 26 oct. 02h01

A phase 3 study of a personalized mRNA vaccine developed by Moderna and Merck showed a 42% reduction in melanoma recurrence or death compared with standard immunotherapy alone.

Crédibilité 78% Manip. 32% Centre
25 octobre 2026
2 au total
Cancer vaccine significantly reduces chance of melanoma patients’ tumours returning, results show
Cancer vaccine significantly reduces chance of melanoma patients’ tumours returning, results show

The Globe and Mail • 25 oct. 18h12

A trial of the mRNA-based vaccine intismeran showed a 42% reduction in melanoma recurrence two years after surgery when added to standard therapy.

Crédibilité 78% Manip. 12% Centre
What's next for cancer vaccines after successful melanoma study
What's next for cancer vaccines after successful melanoma study

STAT • 25 oct. 08h34

A Merck-Moderna mRNA vaccine combined with Keytruda lowered melanoma recurrence or death by 42% in a pivotal study, prompting discussion of broader cancer-vaccine applications.

Crédibilité 73% Manip. 32% Centre
23 octobre 2026
1 au total
Personalized mRNA vaccine for melanoma cut risk of cancer’s return in late-stage trial
Personalized mRNA vaccine for melanoma cut risk of cancer’s return in late-stage trial

NBC News • 23 oct. 18h42

In a phase III study, the Moderna-Merck personalized mRNA vaccine intismeran reduced melanoma recurrence and death by 42% when added to Keytruda, compared with Keytruda alone.

Crédibilité 71% Manip. 32% Centre
22 octobre 2026
2 au total
Moderna, Merck shares fall on eagerly anticipated cancer vaccine results
Moderna, Merck shares fall on eagerly anticipated cancer vaccine results

BioPharma Dive • 22 oct. 22h24

A combined vaccine and Keytruda regimen reduced the relative risk of disease recurrence or death by 42% in advanced melanoma, meeting expectations, while the companies' stocks fell after the announcement.

Crédibilité 71% Manip. 8% Centre
Moderna and Merck say their mRNA cancer vaccine cut death, recurrence by 42%
Moderna and Merck say their mRNA cancer vaccine cut death, recurrence by 42%

Ars Technica • 22 oct. 22h12

Merck and Moderna reported that their personalized mRNA vaccine combined with Keytruda reduced the risk of death or recurrence by 42% in patients with resected melanoma, and lowered distant metastasis risk by 38%.

Crédibilité 78% Manip. 7% Centre

Événements liés